Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al
This essentially forces morning dosing for most people
Retatrutide is an investigational, once-weekly injectable peptide that activates three receptors: GLP-1, GIP, and glucagon
(2025) About Harvard Medical School Guides Harvard Medical School Guides delivers compact, practical information on important health concerns
TABLE 2 outlines a practical approach based on the Three Es method that pharmacists can use to systematically educate patients and manage GI AEs associated with GLP-1 RA therapy
The following features would enhance the value of an obesity therapeutic, but would likely be assessed in follow-up trials or even post-approval: Additional efficacy in obesity-related co-morbidities